John H. Tucker - 07 Oct 2025 Form 4 Insider Report for scPharmaceuticals Inc. (SCPH)

Reporting relationship: President and CEO, Director
Issuer ticker: SCPH
Reported as of: 07 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Oct 2025, 16:30:08 UTC
Prior SEC filing: 12 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Rachael Nokes, Attorney-in-fact for John H. Tucker

Key filing fact

John H. Tucker filed Form 4 for scPharmaceuticals Inc. (SCPH) on 07 Oct 2025.

Key facts

This page summarizes John H. Tucker's Form 4 filing for scPharmaceuticals Inc. (SCPH).
6 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 07 Oct 2025, 16:30.

Change

Previous filing in this sequence was filed on 12 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001303480 Primary reporting owner

Tucker John H

Relationship: President and CEO, Director
Address: C/O SCPHARMACEUTICALS INC, 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON
Signature: /s/ Rachael Nokes, Attorney-in-fact for John H. Tucker
Signature date: 07 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCPH transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -122,345
Change %: -28%
Price
Shares after: 318,502
Date: 07 Oct 2025
Ownership: Direct
Footnotes: F1, F2

SCPH transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -318,502
Change %: -100%
Price
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -300,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $3.34
Footnotes: F4

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -84,500
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 84,500
Exercise price: $3.25
Footnotes: F4

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -249,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 249,000
Exercise price: $4.31
Footnotes: F4

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -496,674
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 496,674
Exercise price: $3.81
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

John H. Tucker is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders received per share consideration of $5.35 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one non-tradable contingent value right ("CVR") per share, representing the right to receive one contingent payment of $1.00, in cash,

Footnote F2

(Continued from footnote 1) subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of October 7, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.

Footnote F3

Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time multiplied by $5.35, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.

Footnote F4

Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares (a "Company Option") that is outstanding and unexercised as of immediately prior to the Effective Time and that that has an exercise price per share that is less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each Share subject to such Company Option.